Sattva Sukun Lifecare Board Meeting Outcome
Tavexia Lifecare announced board meeting outcomes, including statutory auditor changes, independent director reappointment, and a proposal to explore acquiring a 60% stake in Meyonex Pharmaceuticals.
ALFA Filings
Every announcement, straight from the exchange
Every Sattva Sukun Lifecare board meeting outcome announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Tavexia Lifecare announced board meeting outcomes, including statutory auditor changes, independent director reappointment, and a proposal to explore acquiring a 60% stake in Meyonex Pharmaceuticals.
Sattva Sukun Lifecare approved a corrigendum to its EOGM notice for a proposed name change to Tavexia Lifecare Limited. The change aligns with new branding strategies.
Sattva Sukun Lifecare Ltd announced its board meeting outcomes on 30 June 2026, approving director appointments and a name change. No dividend, fund raise or results were disclosed.
Sattva Sukun Lifecare approved related party transactions and noted a rights issue fund utilisation report. Financial results were deferred to June 4, 2026, due to ongoing audits.